Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
IPSC
$2.13
$
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
Next Earnings
2026-02-25
Beta
1.76
Average Volume
Market Cap
Last Dividend
CIK
0001850119
ISIN
US15673T1007
CUSIP
15673T100
CEO
Brent Pfeiffenberger
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
140
IPO Date
2021-06-18
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Financial Review: Century Therapeutics (NASDAQ:IPSC) and Hikma Pharmaceuticals (OTCMKTS:HKMPF) | Hikma Pharmaceuticals (OTCMKTS:HKMPF - Get Free Report) and Century Therapeutics (NASDAQ: IPSC - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations. Analyst Ratings This is a summary of current | Defense World | 2026-02-24 01:13:00 |
| IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight | The iPSC-derived NK cells clinical trial analysis report delivers important insights into ongoing research of 15+ pipeline iPSC-derived NK cells drugs, clinical strategies, upcoming therapeutics, and commercial analysis. The iPSC-derived NK cells clinical trial analysis report delivers important insights into ongoing research of 15+ pipeline iPSC-derived NK cells drugs, clinical strategies, upcoming therapeutics, and commercial analysis. | GlobeNewsWire | 2026-02-16 13:00:00 |
| Century Therapeutics: A Very Promising Contender In The Type I Diabetes Mellitus Functional Cure Race | Century Therapeutics is positioned as a leading contender in developing a durable, once-and-done cure for type I diabetes mellitus (T1DM) using its hypoimmune iPSC-derived β-cell therapy, CNTY-813. IPSC's Allo-Evasion platform uniquely targets T-cell, NK-cell, and humoral immunity, potentially offering superior long-term engraftment and immune escape versus competitors like SANA, VRTX, and CRSP. With cash runway to Q1 2029 and a recent $135M PIPE from major biotech funds, IPSC is well-capitalized to advance its T1DM program toward IND submission in 2026 and initial clinical data in 2027. | Seeking Alpha | 2026-02-09 11:15:40 |
| Century Therapeutics (IPSC) Upgraded to Strong Buy: Here's What You Should Know | Century Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). | Zacks Investment Research | 2026-01-22 13:00:22 |
| Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes | PHILADELPHIA, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ('Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced it has entered into a securities purchase agreement for a private placement for initial gross proceeds of approximately $135 million to the Company, before placement agent fees and offering expenses. | Globe News Wire | 2026-01-08 08:00:00 |
| Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain | If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Century Therapeutics (IPSC) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen. | Zacks Investment Research | 2026-01-07 09:55:31 |
| Why Fast-paced Mover Century Therapeutics (IPSC) Is a Great Choice for Value Investors | If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Century Therapeutics (IPSC) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen. | Zacks Investment Research | 2025-12-09 09:57:08 |
| Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference | PHILADELPHIA, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced that the company will participate in the Piper Sandler 37th Annual Healthcare Conference in New York, NY, as follows: | GlobeNewsWire | 2025-11-25 16:01:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 4 | 2026-02-18 | 2026-02-18 | View Filing |
| EFFECT | 2026-02-17 | 2026-02-18 | View Filing |
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| 4 | 2026-02-05 | 2026-02-05 | View Filing |
| S-3 | 2026-02-05 | 2026-02-05 | View Filing |
| 4 | 2026-02-04 | 2026-02-04 | View Filing |
| 4 | 2026-02-04 | 2026-02-04 | View Filing |
| 4 | 2026-02-04 | 2026-02-04 | View Filing |
| 4 | 2026-02-04 | 2026-02-04 | View Filing |
| 8-K | 2026-01-23 | 2026-01-23 | View Filing |
| SC 13G | 2026-01-16 | 2026-01-16 | View Filing |
| SC 13G | 2026-01-16 | 2026-01-16 | View Filing |
| SC 13G | 2026-01-16 | 2026-01-16 | View Filing |
| SC 13G | 2026-01-15 | 2026-01-15 | View Filing |
| SC 13G | 2026-01-15 | 2026-01-15 | View Filing |
| 8-K | 2026-01-12 | 2026-01-12 | View Filing |
| EFFECT | 2026-01-09 | 2026-01-12 | View Filing |
| 8-K | 2026-01-08 | 2026-01-08 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| S-3/A | 2026-01-05 | 2026-01-05 | View Filing |
| SC 13G | 2026-01-05 | 2026-01-05 | View Filing |
| 4 | 2025-12-29 | 2025-12-29 | View Filing |
| 8-K | 2025-12-29 | 2025-12-29 | View Filing |
| 4 | 2025-12-16 | 2025-12-16 | View Filing |
| 4 | 2025-12-12 | 2025-12-12 | View Filing |
| 8-K | 2025-12-12 | 2025-12-12 | View Filing |
| 4 | 2025-12-11 | 2025-12-11 | View Filing |
| 3 | 2025-12-11 | 2025-12-11 | View Filing |
| 4 | 2025-12-10 | 2025-12-10 | View Filing |
| 4 | 2025-12-10 | 2025-12-10 | View Filing |
| 8-K | 2025-12-09 | 2025-12-09 | View Filing |
| DEFA14A | 2025-12-02 | 2025-12-02 | View Filing |
| DEF 14A | 2025-12-02 | 2025-12-02 | View Filing |
| 4 | 2025-11-24 | 2025-11-24 | View Filing |
| PRE 14A | 2025-11-21 | 2025-11-21 | View Filing |
| 4 | 2025-11-20 | 2025-11-20 | View Filing |
| 4 | 2025-11-19 | 2025-11-19 | View Filing |
| SC 13G/A | 2025-11-14 | 2025-11-14 | View Filing |
| 8-K | 2025-11-13 | 2025-11-13 | View Filing |
| 10-Q | 2025-11-13 | 2025-11-13 | View Filing |
| 4 | 2025-11-05 | 2025-11-05 | View Filing |
| 4 | 2025-09-22 | 2025-09-22 | View Filing |
| 4 | 2025-09-10 | 2025-09-10 | View Filing |
| 4 | 2025-09-10 | 2025-09-10 | View Filing |
| 4 | 2025-09-10 | 2025-09-10 | View Filing |
| 8-K | 2025-08-29 | 2025-08-29 | View Filing |
| 4 | 2025-08-18 | 2025-08-18 | View Filing |
| 10-Q | 2025-08-14 | 2025-08-14 | View Filing |
| 8-K | 2025-08-14 | 2025-08-14 | View Filing |
| 4 | 2025-08-06 | 2025-08-06 | View Filing |
| S-3 | 2025-07-10 | 2025-07-10 | View Filing |
| 8-K | 2025-07-07 | 2025-07-07 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 8-K | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-11 | 2025-06-11 | View Filing |
| 4 | 2025-06-11 | 2025-06-11 | View Filing |
| 4 | 2025-06-11 | 2025-06-11 | View Filing |
| 4 | 2025-06-11 | 2025-06-11 | View Filing |
| 4 | 2025-05-20 | 2025-05-20 | View Filing |
| SC 13G/A | 2025-05-15 | 2025-05-15 | View Filing |
| 10-Q | 2025-05-15 | 2025-05-15 | View Filing |
| 8-K | 2025-05-15 | 2025-05-15 | View Filing |
| 4 | 2025-05-07 | 2025-05-07 | View Filing |
| 4 | 2025-05-07 | 2025-05-07 | View Filing |
| ARS | 2025-04-22 | 2025-04-22 | View Filing |
| DEFA14A | 2025-04-22 | 2025-04-22 | View Filing |
| DEF 14A | 2025-04-22 | 2025-04-22 | View Filing |
| S-8 | 2025-03-20 | 2025-03-20 | View Filing |
| 8-K | 2025-03-19 | 2025-03-19 | View Filing |
| 10-K | 2025-03-19 | 2025-03-19 | View Filing |
| 4 | 2025-03-12 | 2025-03-12 | View Filing |
| 4 | 2025-03-12 | 2025-03-12 | View Filing |
| 4 | 2025-03-12 | 2025-03-12 | View Filing |
| 4 | 2025-03-12 | 2025-03-12 | View Filing |
| 4 | 2025-03-12 | 2025-03-12 | View Filing |
| 4 | 2025-03-12 | 2025-03-12 | View Filing |
| 8-K | 2025-02-28 | 2025-02-28 | View Filing |
| 4 | 2025-02-20 | 2025-02-20 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| 4 | 2025-02-05 | 2025-02-05 | View Filing |
| 4 | 2025-02-05 | 2025-02-05 | View Filing |
| 8-K | 2025-01-13 | 2025-01-13 | View Filing |
| 8-K | 2024-12-13 | 2024-12-13 | View Filing |
| 4 | 2024-12-06 | 2024-12-06 | View Filing |
| SC 13G | 2024-11-27 | 2024-11-27 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G/A | 2024-11-12 | 2024-11-12 | View Filing |
| 4 | 2024-11-05 | 2024-11-05 | View Filing |
| 4 | 2024-11-05 | 2024-11-05 | View Filing |
| 8-K | 2024-11-05 | 2024-11-05 | View Filing |
| 10-Q | 2024-11-05 | 2024-11-05 | View Filing |
| SC 13G/A | 2024-10-25 | 2024-10-25 | View Filing |
| 4 | 2024-10-16 | 2024-10-16 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Price Action Strategy | 263.02% | 0.69 | 6 | 1.14 | 1.29 | 175.33 |
| Quantum Inspired Strategy | 231.36% | 0.9 | 20 | 0.99 | 1.44 | 143.67 |
| Choppiness Index Strategy | 108.50% | 0.9 | 39 | 0.94 | 0.87 | 20.82 |
| xxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |